| Primary |
| Drug Use For Unknown Indication |
20.0% |
| Pulmonary Hypertension |
14.3% |
| Diarrhoea |
8.6% |
| Hypothyroidism |
8.6% |
| Myocardial Infarction |
8.6% |
| Pancreatic Carcinoma Metastatic |
8.6% |
| Angioplasty |
5.7% |
| Atrial Fibrillation |
5.7% |
| Helicobacter Infection |
5.7% |
| Atherosclerosis Prophylaxis |
2.9% |
| Hyperuricaemia |
2.9% |
| Osteonecrosis |
2.9% |
| Product Used For Unknown Indication |
2.9% |
| Prophylaxis |
2.9% |
|
| International Normalised Ratio Increased |
17.6% |
| Septic Shock |
17.6% |
| Bilirubin Conjugated Increased |
5.9% |
| Blood Amylase Increased |
5.9% |
| Blood Creatinine Increased |
5.9% |
| Haematuria |
5.9% |
| Hepatitis |
5.9% |
| Melaena |
5.9% |
| Muscle Haemorrhage |
5.9% |
| Prothrombin Level Abnormal |
5.9% |
| Rectal Haemorrhage |
5.9% |
| Renal Failure |
5.9% |
| Shock Haemorrhagic |
5.9% |
|
| Secondary |
| Drug Use For Unknown Indication |
31.4% |
| Product Used For Unknown Indication |
15.0% |
| Atrial Fibrillation |
12.0% |
| Hypertension |
9.0% |
| Pulmonary Embolism |
3.6% |
| Depression |
2.8% |
| Deep Vein Thrombosis |
2.8% |
| Type 2 Diabetes Mellitus |
2.7% |
| Thrombosis Prophylaxis |
2.6% |
| Cardiac Failure |
2.5% |
| Arrhythmia |
1.9% |
| Phlebitis |
1.8% |
| Urinary Tract Infection |
1.7% |
| Prophylaxis |
1.6% |
| Bronchitis |
1.5% |
| Essential Hypertension |
1.4% |
| Pain |
1.4% |
| Hypothyroidism |
1.4% |
| Unevaluable Event |
1.4% |
| Dyslipidaemia |
1.3% |
|
| International Normalised Ratio Increased |
20.3% |
| Vomiting |
6.7% |
| Renal Failure Acute |
6.6% |
| Rectal Haemorrhage |
6.2% |
| Subdural Haematoma |
5.9% |
| Toxic Skin Eruption |
5.9% |
| Haematoma |
5.5% |
| Muscle Haemorrhage |
5.5% |
| Renal Failure |
5.5% |
| Overdose |
4.7% |
| Thrombocytopenia |
4.5% |
| Neutropenia |
3.8% |
| Shock Haemorrhagic |
2.8% |
| Prothrombin Level Decreased |
2.6% |
| Transaminases Increased |
2.5% |
| Vascular Purpura |
2.5% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
2.1% |
| Interstitial Lung Disease |
2.1% |
| Peritoneal Haemorrhage |
2.0% |
| Weight Decreased |
2.0% |
|
| Concomitant |
| Drug Use For Unknown Indication |
27.3% |
| Product Used For Unknown Indication |
18.7% |
| Hypertension |
11.1% |
| Atrial Fibrillation |
8.9% |
| Cardiac Failure |
3.8% |
| Multiple Myeloma |
3.4% |
| Arrhythmia |
2.7% |
| Type 2 Diabetes Mellitus |
2.5% |
| Pain |
2.4% |
| Thrombosis Prophylaxis |
2.3% |
| Osteoporosis |
2.0% |
| Unevaluable Event |
1.9% |
| Prophylaxis |
1.9% |
| Rheumatoid Arthritis |
1.9% |
| Depression |
1.8% |
| Diabetes Mellitus |
1.8% |
| Insomnia |
1.5% |
| Ill-defined Disorder |
1.5% |
| Pulmonary Arterial Hypertension |
1.4% |
| Hiv Infection |
1.3% |
|
| Renal Failure Acute |
19.3% |
| Renal Failure |
10.7% |
| Thrombocytopenia |
7.0% |
| Vomiting |
6.7% |
| Malaise |
4.7% |
| Somnolence |
4.7% |
| Toxic Skin Eruption |
4.7% |
| Weight Decreased |
4.1% |
| Hyponatraemia |
3.9% |
| Neutropenia |
3.6% |
| Orthostatic Hypotension |
3.6% |
| Pyrexia |
3.5% |
| International Normalised Ratio Increased |
3.3% |
| Lung Disorder |
3.2% |
| Rhabdomyolysis |
3.2% |
| Pancytopenia |
2.9% |
| Sepsis |
2.8% |
| Urinary Tract Infection |
2.8% |
| Syncope |
2.7% |
| Overdose |
2.6% |
|
| Interacting |
| Drug Use For Unknown Indication |
33.5% |
| Atrial Fibrillation |
13.6% |
| Product Used For Unknown Indication |
10.0% |
| Hypertension |
5.1% |
| Unevaluable Event |
4.9% |
| Bronchitis |
3.3% |
| Back Pain |
3.2% |
| Thrombosis Prophylaxis |
3.2% |
| Arrhythmia |
2.9% |
| Lung Disorder |
2.8% |
| Urinary Tract Infection |
2.3% |
| Depression |
2.3% |
| Cardiac Failure |
2.0% |
| Prophylaxis |
2.0% |
| Type 2 Diabetes Mellitus |
1.7% |
| Hypercholesterolaemia |
1.6% |
| Pain |
1.6% |
| Dyslipidaemia |
1.4% |
| Phlebitis |
1.4% |
| Sciatica |
1.2% |
|
| International Normalised Ratio Increased |
41.1% |
| Drug Interaction |
7.3% |
| Overdose |
5.5% |
| Rectal Haemorrhage |
5.5% |
| Subdural Haematoma |
5.5% |
| Melaena |
5.2% |
| Muscle Haemorrhage |
3.9% |
| International Normalised Ratio Decreased |
2.9% |
| Shock Haemorrhagic |
2.9% |
| Subcutaneous Haematoma |
2.6% |
| Prothrombin Level Decreased |
2.4% |
| Haematoma |
2.1% |
| Haematuria |
1.8% |
| Prothrombin Time Ratio Decreased |
1.8% |
| Renal Failure |
1.8% |
| Anaemia |
1.6% |
| Pallor |
1.6% |
| Respiratory Failure |
1.6% |
| Wound Haemorrhage |
1.6% |
| Gastrointestinal Haemorrhage |
1.3% |
|
